Blood Advances · 2022 · 44 citations · 14 references
Life SciencesOncologyPharmacotherapyCancer ImmunologyImmuno-oncology PharmacotherapyImmunotherapyCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesCar T Cell TrialsExpansion Cohort DesignProgressive Disease AssessmentProgressive Disease QuantificationRituximab-based TherapyT Cell-based ImmunotherapyT-cell Therapy
For Pola-BR, the objective response rate (ORR) was 62.5% (complete response [CR] rate was 50%). Median progression-free survival (PFS) a at 9.2 months and overall survival (OS) at 12.4 months were both superior for Pola-BR. 9 A single-arm expansion cohort identified primary refractory
14